Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thoughts on podras.
I’m hoping good results shortly leading to a partnership. I hope they aren’t stubborn and try to go it alone. Time is ticking.
Man
Considering the track record of the company and the recent price action this is a real possibility.
This company is just so frickin frustrating.
Only news we really ever get is negative.
How about some positive news like
Podras partnership and spinning off podras.
Angelo
I think it is at least that much. I recall closer to $100m. In any event don’t see odidi selling.
Wouldn’t it be great if they presented great podras news for a potentially transformative product at a time when many shares are locked, and we have a rush to get in through a small door.
What is odidis percentage holding? Among those two and odidi I think we are close to 65 percent.
Man now is a great time to unleash great podras news - a revolutionary technology.
That’s funny and unfortunately so true
One of the major problems here. Major lack of transparency. And there is no good reason for it other than management incompetence.
Will ubs now be disposing of these shares? What does it intend to do with them? That is why we need to know why they were repurchased.
Most likely are direct repurchases from clients. Clients bought stock at earlier offerings. For some reason ubs was required to repurchase those shares. These are not likely shares purchased on the open market. Hence no impact on share price.
They are existing shares now consolidated. Question is why was ubs required to repurchase shares from what were likely some of the buyers of previous offerings.
Looks like ubs was required to buy back the stock from some of its clients if I’m reading correctly. Wonder what the performance standards were that prompted the purchase.
Musky
Please clarify what you mean
Hope so but wondering if another offering in play. That volume often precedes an offering.
Needs good podras news.
Musky
Why would they tell the mm there is news coming
Your a good man fisherman.
Mike sorry for your pain. I will be most excited for you when we recover.
Fabius
Do I really think Purdue is interested in the product.
I’ve gone back and forth on that one.
Recently I think no and they are just trying to squash another little guy to prevent another competitor. That as opposed to trying to get the product on the cheap.
If they really wanted the product something would have happened by now to get it.
Hope I’m wrong but time continues to tick with nothing.
What is interesting is that patient seems to be stating that trials have started. Why hasn’t ipci officially announced it.
They may want cover if the results come back poorly. Or maybe it is because they have an interested potential partner and they are keeping the study on the downlow. Or maybe trials have not yet begun.
We need new buyers. Podras positive news may be the ticket.
Last I heard anything trials likely underway with results due within next month. No official announcement from company but appears to be the case.
Anyone have any additional insight into the podras studies?
Good news.
Why September 28th as the compliance date?
Is this date related to info provided at the hearing?
I don’t read too much into that other than patient has integrity. He is the mouthpiece to shareholders and is putting his money where his mouth is.
It is still troubling that the odidis have not bought at these levels. This is their baby. Not sticking up for your children when they are being pounded is not a good sign.
That would even be better.
Do you think Purdue has a hand in the manipulation or its purely scalpers.
What do you think probability of a partner is in next 3 months for regabatin and podras.
I’m not sure I see a way out of more imminent dilution. I just don’t see any large payments or it would have happened already
Good points. I wonder if good partners may provide the company some substance to counter the manipulation.
I really hope they spin off the generics from nda. It could provide a catalyst to nail the shorts.
Also curious why Boyd is lying in the weeds and has not sent one of his love letters.
I doubt it too but would like to see the company taking some aggressive action.
Otherwise it seems they have essentially written off seroquel.
Seroquel was supposed to be the safety net for advancement if the pipeline.
Seems like one to two things is transpiring with mnk
It either does not care about sales and is devoting little if any resources, or
It bought the license to bury it to drive the drive the price down for a cheap takeover.
Think first is most likely (as it has said as much) but who knows
It provides options. Currently we have none.
No revenue from mnk. Why leave it there.
Hate to be negative but that seems to be the m.o. of the company - hope things change.
At least this way they wrestle some control back.
How can they even think of generating revenue on it when it is stuck
Very curious to me why ipci has not sued mnk to get the license back.
Wonder if it is a potential partner for regabatin or podras.
Why else would they not be taking action. It is ridiculous.
I think that is likely the hold up. Partner is thinking like you. Odidi wants more.
Odidi likely doesn’t fully comprehend that the perception of the company from an investor and partner perspective has turned negative and the only thing that will change this is a change in management or a demonstration of competence. Demonstration of confidence will take a while, however, and time is not on our side.
Was fishing opener this weekend in wisc?
Samsa
Let me ask you a question
Would you be willing to put up your own money with someone you didn’t really trust even if you thought he had a great product? And what about if you are concerned whether that person will be around to see it through?
Would those factors affect how much you are willing to put on the table?
Viability and trust I do think play a factor in the amount of partnership money.
Agree.
When you were there did you get a feel for what the 50 people were doing.
I’ve asked and never get a straight answer - things like they are working on the andas
I just don’t get it. Why the need to 50 employees? No new products. The nda studies are outsourced.
Did they appear to be friends or relatives of odidi?
Don’t get me wrong. It like to remain positive. But that is what caused me to overlook some things.
Appreciate you taking the time to visit the company with impact.
I really hope they can turn it around.
Thanks for sharing your thoughts.
And by the way
What is the deal with ipci application for approval of the other strengths of focalin
No mention if they are still pursuing that
And their cash burn is terrible considering what they are producing.
Where is that 13m annually being spend. No transparency l
Come on mopar, really.
Those approvals other than focalin have have had a negative financial effect on the company.
I’m stuck in this stock and at this price worth staying, but let’s be straight here.
The management, transparency and execution has been just short of a disaster.
And by the way what is the 5th approval. I count 4.
Compared to companies that don’t hide the ball, that at least partially meet their own goals, that have shown competence in obtaining approvals for their products, and are fiscally prudent where viability is not a recurring issue (in other words companies to which other companies would be reasonably comfortably outlaying money for a partnership)
Samsa
Your numbers and logic don’t jive with the company’s history and reputation. I really hope I’m proven wrong but I think your off by at least a factor is 10.
Grill
Really good info. Your hypothesis on the potential hold up is interesting
I hadn’t thought of it. There must be a reason and that would certainly be more positive than low-ball offers.
Unfortunately at this time the default outlook for this company is pessimism rather than optimism. And without more information default prevails.
Thanks for sharing your thoughts and info.
Is pregabalin a molecule susceptible to overdose?
Would love for you to be right
But why is it not partnered yet?
Have to think numbers are well below that. Otherwise they would have opened the gate.
Tilly
Any forecast of how much they could get in annual licensing revenue for each on the foreign markets.
How difficult is penetration in the ex us markets
Really curious why they are waiting on this unless partner will not pay for all trial costs. Get the pipeline moving.
They got 50 people working and tons of secret stuff in the hopper - or so they say.
Honestly what the f are the 50 people doing?
I agree with you wm. If Sig upfront cash was possible it would already be signed.
The imminent issue again is cash. My guess is they hope for positive podras trials and then dilute again.
Fabius
Any change in seroquel or focalin numbers
$13m market cap. This is like the twilight zone.
I projected they would have $13m in annual revenue at this point.